Monash IVF Group (MVF) H2 2026 earnings summary

Executive summary

• FY26 revenue was resilient at AUD 269.5 million, down 0.9% year-over-year, with underlying EBITDA of AUD 53.4 million and underlying NPAT of AUD 16.1 million, both impacted by a AUD 1.4 million asset write-off and margin pressures.

• The year transitioned from operational reset and stabilization in the first half to renewed momentum and market share gains in the second half, supported by the Nurture 2030 strategic plan.

• International segment delivered record results, with revenue up 15% to AUD 21.2 million and EBITDA up 10% to AUD 4.2 million, driven by strong growth in Asia.

• Leadership and governance were refreshed at executive and board levels, with new appointments and succession planning to support strategic direction.

• Strategic investments in new clinics, expanded surgical capacity, and productivity programs were completed.

Financial highlights

• Revenue decreased by less than 1% year-over-year to AUD 269.5 million, with domestic softness offset by international genetics and ancillary growth.

• Underlying EBITDA margin was 19.8%, down 460–560 basis points year-over-year, reflecting cost pressures and market share losses in the first half.

• Fully franked FY26 dividend of 2.5 cents per share, representing a 60% payout ratio.

• Operating cash flow improved to AUD 36.7 million, with a cash conversion ratio of 85%.

• Net debt increased to AUD 101.2 million due to elevated CapEx and non-regular items; CapEx totaled AUD 23.8 million and is expected to drop by 50% in FY27.

Outlook and guidance

• FY27 is expected to see a return to growth in the domestic ARS market and continued acceleration in Asia, with strengthened financial performance and reduced CapEx.

• Focus areas include organic volume growth, market share, EBITDA margin, cash conversion, and leveraging completed capital investments.

• CapEx to decline by more than 50% from FY26, with emphasis on asset optimization and utilization.

• Depreciation, amortization, and net interest expense expected to remain broadly steady in FY27.

• Well positioned to implement evolving regulatory standards and lead in innovation.